Gestalt Partners with Indiana ADDL to Enhance Digital Pathology and Diagnostic Services
- Gestalt partners with Indiana ADDL to enhance digital pathology capabilities for improved diagnostic services and research.
- The PathFlow® platform will streamline ADDL's workflows and support advanced diagnostic tools and collaboration among pathologists.
- Lisa-Jean Clifford highlights the partnership's potential to transform laboratory medicine and improve healthcare outcomes in the community.
Gestalt Partners with Indiana Animal Disease Diagnostic Laboratory to Advance Digital Pathology
Gestalt, a frontrunner in digital pathology and AI-driven workflow solutions, has embarked on a significant partnership with the Indiana Animal Disease Diagnostic Laboratory (ADDL) at Purdue University. This collaboration is poised to enhance the ADDL's clinical, educational, and research capabilities in digital pathology, aligning with their mission to improve diagnostic services for residents of Indiana and beyond. By adopting Gestalt's PathFlow® platform, the ADDL aims to streamline its workflows and foster collaboration among pathologists, while integrating advanced AI tools for diagnostics and research.
The PathFlow platform offers a comprehensive solution that facilitates advanced digital slide viewing, case evaluation, annotation, and archiving. It supports complete diagnostic workflows, ranging from case organization to reporting and storage. The initial deployment will focus on the anatomical pathology (AP) module, which empowers pathologists with enhanced workflow efficiency and collaborative capabilities through access to whole slide images. The ADDL envisions broader applications of the PathFlow platform to support educational and research workflows, equipping students, faculty, and scientists with the latest tools in digital pathology training and discovery. Dr. Christopher Gaudette, a veterinary diagnostician at ADDL, underscores that this partnership signifies a pivotal advancement in digital pathology across various domains.
Lisa-Jean Clifford, President of Gestalt, expresses pride in this collaboration, highlighting a shared vision to develop scalable and interoperable solutions that enhance diagnostics, education, and research. This partnership exemplifies Gestalt's commitment to transforming laboratory medicine through innovative technology and strategic collaborations. As the field of digital pathology continues to evolve, Gestalt's partnership with the ADDL not only strengthens their position in the industry but also promises to lead to significant improvements in healthcare outcomes for communities served by the laboratory.
In a related development, Pangea Laboratory has announced a strategic collaboration with Gene Solutions to validate AI-driven liquid biopsy assays intended for cancer detection, characterization, and monitoring. This partnership aims to enhance cancer diagnosis capabilities in U.S. CLIA/CAP laboratory settings, highlighting the growing trend of integrating AI technology into diagnostic processes.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

